Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Prolonged seizures [status epilepticus (SE)] constitute a neurological emergency that can permanently damage the brain. SE results from a failure of the normal mechanisms to terminate seizures; in particular, γ‐amino butyric acid‐mediated inhibition, and benzodiazepine anticonvulsants are often incompletely effective. ATP acts as a fast neurotransmitter via ionotropic ligandgated P2X receptors. Here we report that SE induced by intra‐amygdala kainic acid in mice selectively increased hippocampal levels of P2X7 receptors relative to other P2X receptors. Using transgenic P2X7 reporter mice expressing enhanced green fluorescent protein, we identify dentate granule neurons as the major cell population transcribing the P2X7 receptor after SE. Pretreatment of mice with an intracerebroventricular microinjection of 1.75 nmol A438079, a P2X7 receptor antagonist, reduced seizure duration by 58% and reduced seizure‐induced neuronal death by 61%. Injection of brilliant blue G (1 pmol), another selective antagonist, reduced seizure duration by 48% and was also neuroprotective. A438079 was seizure‐suppressive when injected shortly after induction of SE, and coinjection of A438079 with lorazepam 60 min after triggering SE, when electrographic seizure‐responsiveness to lorazepam had decreased, also terminated SE. Our results suggest that P2X7 receptor antagonists may be a promising class of drug for seizure abrogation and neuroprotection in SE.—Engel, T., Gomez‐Villafuertes, R., Tanaka, K., Mesuret, G., Sanz‐Rodriguez, A., Garcia‐Huerta, P., Miras‐Portugal, M. T., Henshall, D. C., Diaz‐Hernandez, M. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 26, 1616‐1628 (2012). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The P2X 7 Receptor Drives Microglial Activation and Proliferation: A Trophic Role for P2X 7 R Pore
Monif, M., Reid, C. A., Powell, K. L., Smart, M. L., & Williams, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5512-08.2009 · Cited by 374
Deuchars, S. A., Atkinson, L., Brooke, R. E., Musa, H., Milligan, C. J., Batten, T. F. C., Buckley, N. J., Parson, S. H., & Deuchars, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07143.2001 · Cited by 287
Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor-/- mice
Papp, L., Vizi, E. S., & Sperlágh, B. (2004) · Neuroreport · doi:10.1097/00001756-200410250-00017 · Cited by 102
Atkinson, L., Batten, T. F. C., Moores, T. S., Varoqui, H., Erickson, J. D., & Deuchars, J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.065 · Cited by 80
P2X7 receptors enhance glutamate release in hippocampal hilar neurons
Cho, J.-H., Choi, I.-S., & Jang, I.-S. (2010) · Neuroreport · doi:10.1097/wnr.0b013e32833d9142 · Cited by 37
Cited by
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Bartlett, R., Stokes, L., & Sluyter, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008003 · Cited by 393
P2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
van Vliet, E. A., Aronica, E., Vezzani, A., & Ravizza, T. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12444 · Cited by 259
P2X7 Receptors: Channels, Pores and More
Volonte, C., Apolloni, S., D. Skaper, S., & Burnstock, G. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712803581137 · Cited by 254
The microglial ATP‐gated ion channel P2X7 as a CNS drug target
Bhattacharya, A., & Biber, K. (2016) · Glia · doi:10.1002/glia.23001 · Cited by 221
“In addition to seizure suppression, Engel et al., also demonstrated protection against neurodegeneration, microglial activation and IL-1 b release in epileptic mice treated with P2X7 antagonists (Engel et al., 2012).”
BackgroundNeuronal P2X7 Receptors Revisited: Do They Really Exist?
Illes, P., Khan, T. M., & Rubini, P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3103-16.2017 · Cited by 179
L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade
Jourdain, P., Allaman, I., Rothenfusser, K., Fiumelli, H., Marquet, P., & Magistretti, P. J. (2016) · Scientific Reports · doi:10.1038/srep21250 · Cited by 116
Jimenez-Mateos, E. M., Arribas-Blazquez, M., Sanz-Rodriguez, A., Concannon, C., Olivos-Ore, L. A., Reschke, C. R., Mooney, C. M., Mooney, C., Lugara, E., Morgan, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17486 · Cited by 103
Self-citationP2X7 Receptor: A Potential Therapeutic Target for Depression?
Deussing, J. M., & Arzt, E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.07.005 · Cited by 97
Martínez-Frailes, C., Di Lauro, C., Bianchi, C., de Diego-García, L., Sebastián-Serrano, Á., Boscá, L., & Díaz-Hernández, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00143 · Cited by 83
Self-citationWilkaniec, A., Gąssowska, M., Czapski, G. A., Cieślik, M., Sulkowski, G., & Adamczyk, A. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9567-2 · Cited by 61
“Deregulation of P2X7 receptor has previously been indicated to be common for diverse situations of brain damage, such as ischemia [61, 62], traumatic brain injury [63], spinal cord injury [64], epilepsy [65], Alzheimer’s disease [59, 66], Parkinson’s disease [67], prion disease [68], or Huntington’s disease [69].”
BackgroundThe role of Na+‐K+‐ATPase in the epileptic brain
Sun, J., Zheng, Y., Chen, Z., & Wang, Y. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13893 · Cited by 55
Barros‐Barbosa, A. R., Fonseca, A. L., Guerra‐Gomes, S., Ferreirinha, F., Santos, A., Rangel, R., Lobo, M. G., Correia‐de‐Sá, P., & Cordeiro, J. M. (2016) · Epilepsia · doi:10.1111/epi.13263 · Cited by 48
“Conversely, Jimenez-Pacheco’s group reported increased neocortical expression of the P2X7R after status epilepticus induced by injecting kainic acid into the amygdala of mice and showed that the P2X7R antagonist, A-438079, exerts an anticonvulsant effect.(5,6,34) These apparently contradictory findings may suggest tha…”
BackgroundMethodResultInfluentialPleiotropic Roles of P2X7 in the Central Nervous System
Kanellopoulos, J. M., & Delarasse, C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00401 · Cited by 48
“This mechanism allows a GSDMD-mediated IL-1β release without cell lysis (reviewed in Evavold and Kagan, 2018).”
BackgroundPérez-Núñez, R., Chamorro, A., González, M. F., Contreras, P., Artigas, R., Corvalán, A. H., van Zundert, B., Reyes, C., Moya, P. R., Avalos, A. M., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02677-7 · Cited by 24
Barros-Barbosa, A. R., Lobo, M. G., Ferreirinha, F., Correia-de-Sá, P., & Cordeiro, J. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.026 · Cited by 23
Metadata
- Authors
- Engel, T., Gomez‐Villafuertes, R., Tanaka, K., Mesuret, G., Sanz‐Rodriguez, A., Garcia‐Huerta, P., Miras‐Portugal, M. T., Henshall, D. C., & Diaz‐Hernandez, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2011-12-23
- Volume
- 26
- Issue
- 4
- Pages
- 1616-1628
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2160855062
- Cited by
- 194
- References
- 5
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.